Inhibitor for reduction in type i collagen production

Abstract

To find a substance having an inhibitory effect on the reduction in type I collagen production, particularly that is caused by glycation, among highly safe natural substances, and to provide an inhibitor for reduction in type I collagen production which comprises the found substance as an active ingredient.SOLUTION: An inhibitor for reduction in type I collagen production comprises yeast extract as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to an agent for suppressing a decrease in type I collagen production. [Background technology]

[0002] The dermis and epidermis of the skin are composed of epidermal cells, fibroblasts, and dermal extracellular matrix such as type I collagen that is located outside these cells and supports the skin structure. In young skin, these skin tissues maintain homeostasis, ensuring the skin's moisturizing function, flexibility, elasticity, etc., and the skin is maintained in a firm, shiny, and moist appearance.

[0003] A decrease in the production of type I collagen, a major component of the dermal extracellular matrix, leads to the degeneration and decomposition of the dermal extracellular matrix, such as type I collagen. As a result, the stratum corneum begins to peel abnormally, the skin loses firmness and luster, and aging symptoms such as rough skin and wrinkles appear. Such changes associated with skin aging, such as the formation of wrinkles, loss of firmness, and reduced elasticity, are related to the decrease in the production of type I collagen and the denaturation of type I collagen.

[0004] Carbohydrates, which are extremely important as an energy source for humans and other living organisms, are known to undergo glycation reactions (glycation) with proteins. Glycation is a series of reactions in which the first step is a nonenzymatic reaction between the carbonyl group of carbohydrates and the amino group of proteins, etc., followed by a Schiff base and an Amadori compound to form final glycation products. Glycation nonenzymatically modifies proteins with sugars, causing denaturation of the proteins and cross-linking between proteins, resulting in reduced or lost function of the proteins. Glycation not only causes direct damage by modifying and changing the structure of proteins that make up the dermal extracellular matrix, such as type I collagen, but also has effects such as inducing cellular responses by being recognized by receptors that use glycated proteins as ligands.

[0005] For example, when type I collagen is glycated and becomes abnormally cross-linked, it causes a decrease in the skin's moisturizing function and elasticity, and dullness due to yellowing, etc. Furthermore, since abnormally cross-linked type I collagen is difficult to decompose by decomposing enzymes such as collagenase, normal type I collagen, etc. is decomposed by the expressed collagenase, etc., causing problems such as a decrease in the amount of type I collagen produced.

[0006] Therefore, if the decrease in the amount of type I collagen produced due to glycation can be suppressed, it is expected to be useful for preventing or improving the decrease in skin elasticity, dullness, etc. Conventionally, N-phenacylthiazolium bromide is known as a compound having an anti-glycation effect (see Non-Patent Document 1). In addition, for example, an extract from mugwort is known as a component derived from a natural product having an anti-glycation effect (see Patent Document 1). [Prior art documents] [Patent documents]

[0007] [Patent Document 1] JP 2001-122758 A [Non-patent literature]

[0008] [Non-Patent Document 1] Vasan S. et al.,Nature,July 18, 1996,Vol. 82,No. 6588,p.275-278 Summary of the Invention [Problem to be solved by the invention]

[0009] The present invention aims to find a substance that has the effect of inhibiting a decrease in type I collagen production, particularly a decrease in type I collagen production caused by glycation, from among highly safe natural products, and to provide an agent for inhibiting a decrease in type I collagen production that contains this substance as an active ingredient. [Means for solving the problem]

[0010] In order to solve the above problems, the agent for inhibiting a decrease in type I collagen production of the present invention contains yeast extract as an active ingredient and can inhibit a decrease in type I collagen production caused by glycation in skin fibroblasts. Effect of the Invention

[0011] According to the present invention, it is possible to provide an agent for inhibiting a decrease in type I collagen production, which comprises as an active ingredient a substance having an effect of inhibiting a decrease in type I collagen production, in particular an effect of inhibiting a decrease in type I collagen production caused by glycation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] An embodiment of the present invention will now be described in detail. The agent for suppressing a decrease in type I collagen production according to this embodiment contains a yeast extract as an active ingredient.

[0013] The extraction raw material used to obtain the active ingredient of the inhibitor for inhibiting a decrease in type I collagen production according to this embodiment is yeast. Yeast is a general term for fungi that are spherical or elliptical single-celled organisms with a diameter of about 5 to 10 μm, and has the property of decomposing sugars and carrying out alcoholic fermentation. As the extraction raw material, yeasts (scientific names: Saccharomyces cerevisiae, Saccharomyces veronae) belonging to the genus Saccharomyces, such as baker's yeast, brewer's yeast, sake yeast (seishu yeast), and wine yeast (wine yeast), can be used.

[0014] The yeast extract in this embodiment may be obtained by a method capable of extracting soluble components contained in the yeast as the extraction raw material. The yeast extract may be, for example, an extract obtained by an autolysis method in which conditions such as pH and temperature are set within a specific range that is unsuitable for yeast growth to induce autolysis of yeast, a hydrolysis method in which the cell walls of yeast are solubilized using an acid such as hydrochloric acid, or an enzymatic decomposition method in which the cell walls of yeast are solubilized using an enzyme such as a protease. The yeast extract in this embodiment may be a diluted product, concentrated product, dried product, or the like obtained by diluting, concentrating, drying, or the like the yeast extract obtained by the above method according to a conventional method.

[0015] As will be apparent from the examples described later, the yeast extract thus obtained has an effect of suppressing a decrease in type I collagen production, particularly an effect of suppressing a decrease in type I collagen production caused by glycation in skin fibroblasts, and this effect can be utilized to use the yeast extract as an active ingredient of an agent for suppressing a decrease in type I collagen production.

[0016] The inhibitor of a decrease in type I collagen production of the present embodiment may consist of yeast extract alone, or may be a formulation of the yeast extract.

[0017] The yeast extract can be formulated into any dosage form, such as powder, granules, tablets, liquid, etc., according to a conventional method using a pharma- ceutically acceptable carrier such as dextrin, cyclodextrin, or any other auxiliary agent. In this case, examples of auxiliary agents that can be used include excipients, binders, disintegrants, lubricants, stabilizers, flavorings, and odorants. The yeast extract can be used by blending with other compositions (e.g., skin cosmetics, etc.), and can also be used as an ointment, external liquid, patch, etc.

[0018] If necessary, the inhibitor of a decrease in type I collagen production of the present embodiment can be used as an active ingredient by blending it with another natural extract having an effect of inhibiting a decrease in type I collagen production, in particular an effect of inhibiting a decrease in type I collagen production caused by glycation in skin fibroblasts.

[0019] The method of administration of the inhibitor for the decrease in type I collagen production of this embodiment generally includes percutaneous administration, oral administration, etc., but a method suitable for prevention, treatment, etc. may be appropriately selected depending on the type of disease. The dosage of the inhibitor for the decrease in type I collagen production of this embodiment may also be appropriately increased or decreased depending on the type and severity of the disease, individual differences between patients, administration method, administration period, etc.

[0020] The inhibitor of the present embodiment can suppress the decrease in the production amount of type I collagen through the inhibitory effect of the yeast extract, which is an active ingredient, on the decrease in the production amount of type I collagen, particularly the inhibitory effect on the decrease in the production amount of type I collagen caused by glycation in skin fibroblasts, and can particularly suppress the decrease in the production amount of type I collagen caused by glycation in skin fibroblasts, and as a result, can prevent or improve wrinkle formation in the skin, loss of firmness, loss of elasticity, dullness of the skin, etc. However, the inhibitor of the present embodiment can be used for all applications in which it is meaningful to exert the inhibitory effect on the decrease in the production amount of type I collagen other than these applications.

[0021] In addition, since the inhibitor for the decrease in type I collagen production of the present embodiment has an excellent inhibitory effect on the decrease in type I collagen production, it is suitable for incorporation into, for example, an external skin preparation or an oral composition. In this case, the yeast extract may be incorporated as it is, or an inhibitor for the decrease in type I collagen production formulated from the yeast extract may be incorporated.

[0022] Here, topical skin preparations are not limited to specific classifications and include a wide range of skin cosmetics, quasi-drugs, medicines, etc. that are used percutaneously. Specific examples include ointments, creams, milky lotions, beauty serums, lotions, packs, foundations, lip balms, bath additives, hair tonics, hair lotions, soaps, body shampoos, etc.

[0023] The amount of yeast extract in the topical skin preparation can be adjusted as appropriate depending on the type of topical skin preparation, but a suitable blending rate is 0.0001 to 10 mass%, and a particularly suitable blending rate is 0.001 to 1 mass%.

[0024] The oral composition refers to a composition that is unlikely to cause harm to human health and is taken orally or by administration through the digestive tract in normal social life, and is not limited to administrative classifications such as food, medicine, and quasi-drug. Therefore, the "oral composition" in this embodiment broadly includes general foods, feeds, health foods, health functional foods (foods for specified health uses, foods with nutrient functions, and foods with functional claims), quasi-drugs, medicines, and the like that are taken orally. The oral composition in this embodiment is preferably an oral composition that can display the favorable effects of the yeast extract on the oral composition or its packaging, and is particularly preferably a health functional food (foods for specified health uses, foods with nutrient functions, and foods with functional claims), quasi-drugs, or medicines.

[0025] The amount of yeast extract in the oral composition can be appropriately changed taking into consideration the purpose of use, symptoms, sex, etc., but taking into consideration the general intake of the oral composition to be added, it is preferable that the daily intake of yeast extract for an adult is about 1 to 1000 mg. When the oral composition to be added is in the form of granules, tablets, or capsules, the amount of yeast extract added is usually 0.0001 to 10% by mass, preferably 0.001 to 1% by mass, based on the oral composition to be added.

[0026] Furthermore, since the inhibitor of the present embodiment for inhibiting a decrease in type I collagen production has an excellent effect of inhibiting a decrease in type I collagen production, it can also be suitably used as a reagent for research into the mechanisms of these actions.

[0027] In addition, the type I collagen production decrease inhibitor of this embodiment is preferably applied to humans, but can also be applied to animals other than humans as long as the respective action effects are exerted. EXAMPLES

[0028] The present invention will be described in more detail below by giving Production Examples, Test Examples, etc., but the present invention is not limited to the following Test Examples, etc.

[0029] [Production Example 1] Production of yeast extract 100 g of yeast (Saccharomyces veronae) powder was acid-hydrolyzed and then filtered. The resulting extract was dried to obtain yeast extract (21 g).

[0030] [Test Example 1] Test for inhibitory effect on decrease in type I collagen production Normal human skin fibroblasts (NB1RGB) were cultured for 3 days using DMEM containing 10% FBS. On the 4th day, the medium was replaced with DMEM containing 10% FBS containing 0.6 mM glyoxal (Glyoxal, Sigma), and the medium was further cultured for 3 days to induce glycation, and glycation-induced cells were prepared. As a control, the medium was replaced with DMEM containing 10% FBS without glyoxal on the 4th day, and the medium was similarly cultured for 3 days to prepare non-glycation-induced cells. After culture, the cells were diluted to 20 × 10 4 After dilution to cells / mL, 100 μL was seeded per well on a 96-well plate. After 6 hours, 100 μL of the test sample (see Table 1 for sample concentration) dissolved in DMEM containing 0.25% FBS was added to each well, and the cells were cultured for another 2 days. After culture, the amount of type I collagen in the medium of each well was measured by ELISA, and the inhibition rate (%) of the decrease in type I collagen production was calculated using the following formula.

[0031] Inhibition rate of decrease in type I collagen production (%) = {1-(AC) / (AB)} x 100 In the formula, A represents the "amount of type I collagen produced by non-glycation-induced cells when no test sample is added (sample concentration 0 μg / mL)," B represents the "amount of type I collagen produced by glycation-induced cells when no test sample is added," and C represents the "amount of type I collagen produced by glycation-induced cells when a test sample is added." The results are shown in Table 1.

[0032] [Table 1]

[0033] As shown in Table 1, it was confirmed that the yeast extract has an excellent inhibitory effect on the decrease in type I collagen production, particularly the inhibitory effect on the decrease in type I collagen production caused by glycation in skin fibroblasts. It was also presumed that the inhibitory effect of the yeast extract on the decrease in type I collagen production is concentration-dependent. [Industrial Applicability]

[0034] The inhibitor of a decrease in type I collagen production according to this embodiment can greatly contribute to the prevention or improvement of wrinkles in the skin, loss of firmness, decreased elasticity, dull skin, and the like, which may occur with a decrease in type I collagen production caused by glycation.

Claims

1. 1. An agent for suppressing a decrease in type I collagen production, comprising a yeast extract as an active ingredient.

2. The inhibitor of decrease in type I collagen production according to claim 1, characterized in that it inhibits decrease in type I collagen production caused by glycation in skin fibroblasts.

Images